Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

European Journal of Cancer

Volumn 45, Issue 17, 2009, Pages 2940-2946

  Pivot, Xavier B ^a   Li, Rubi K ^b   Thomas, Eva S ^c   Chung, Hyun Cheol ^d   Fein, Luis E ^e   Chan, Valorie F ^f   Jassem, Jacek ^g   Mendoza, Fernando Hurtado de ^h   Mukhopadyay, Pralay ⁱ   Roché, Henri H ^j  

^a INSERM   (France)

^b ST LUKE S MEDICAL CENTER   (Philippines)

^c KAISER PERMANENTE   (United States)

^d Yonsei University College of Medicine   (South Korea)

^e Centro de Oncologia Rosario   (Argentina)

^f Veterans Memorial Medical Center   (Philippines)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j INSTITUT CLAUDIUS REGAUD   (France)

more..

Author keywords

Breast cancer; Epothilone; ER PR HER2 negative; Ixabepilone; Oestrogen receptor negative; Taxanes; Triple negative

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IXABEPILONE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RISK REDUCTION; SENSORY NEUROPATHY; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL METASTASIS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EPIDEMIOLOGIC METHODS; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70449096190     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.07.015     Document Type: Article

References (44)

1. Sørlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 40 (2004) 2667-2675
2. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51 (1998) 227-238
3. Fisher B., Redmond C., Fisher E.R., and Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6 (1988) 1076-1087
4. Shek L.L., and Godolphin W. Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis. Cancer Res 48 (1988) 5565-5569
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
6. International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2002;94:1054-65.
7. Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 (2006) 1658-1667
8. Sheikh MS, Garcia M, Pujol P, Fontana JA, Rochefort H. Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers? Invas Metast 1994-1995;14:329-36.
9. Rochefort H., Glondu M., Sahla M.E., Platet N., and Garcia M. How to target estrogen receptor-negative breast cancer?. Endocr Relat Cancer 10 (2003) 261-266
10. Cordera F., and Jordan V.C. Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol 33 (2006) 631-641
11. Stanford J.L., and Greenberg R.S. Breast cancer incidence in young women by estrogen receptor status and race. Am J Public Health 79 (1989) 71-73
12. Lee M.C., Patel-Parekh L., Bland K.I., et al. Increased frequency estrogen receptor (ER) negative and aneuploid breast cancer in African American women at all stages of disease: first analysis from the National Cancer Data Base (NCDB). Proc Am Soc Clin Oncol (2007) 25 [Abstract 121]
13. Anderson W.F., Chu K.C., Chatterjee N., Brawley O., and Brinton L.A. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 19 (2001) 18-27
14. Nunes R.A., and Harris L.N. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 3 (2002) 125-135
15. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 8 (2007) 235-244
16. Osborne C.R., Kannan L., Ashfaq R., et al. Clinical and pathological characterization of basal-like breast cancer. Breast Cancer Res Treat (2005) 94 [Abstract 2098]
17. Rodríguez-Pinilla S.M., Sarrió D., Honrado E., et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12 (2006) 1533-1539
18. Tsuda H., Takarabe T., Hasegawa F., Fukutomi T., and Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24 (2000) 197-202
19. Haffty B.G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24 (2006) 5652-5657
20. Pivot X., Dufresne A., and Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer 7 (2007) 543-549
21. Cortes J., and Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 12 (2007) 271-280
22. Lee F.Y., Borzilleri R., Fairchild C.R., et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7 (2001) 1429-1437
23. Altmann K.H., Wartmann M., and O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470 (2000) M79-M91
24. Altmann K.H. The chemistry and biology of epothilones - lead structures for the discovery of improved microtubule inhibitors. In: Liang X.T., and Fang W.S. (Eds). Medicinal chemistry of bioactive natural products (2006), Wiley and Sons, Hoboken, NJ 1-34
25. Nogales E., Wolf S.G., Khan I.A., Ludueña R.F., and Downing K.H. Structure of tubulin at 6.5 Å and location of the taxol-binding site. Nature 375 (1995) 424-427
26. Bode C.J., Gupta Jr. M.L., Reiff E.A., Suprenant K.A., Georg G.I., and Himes R.H. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 41 (2002) 3870-3874
27. Nettles J.H., Li H., Cornett B., Krahn J.M., Snyder J.P., and Downing K.H. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 305 (2004) 866-869
28. ® resistance recapitulates the phenotype of its origin, has altered β-tubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res (2006) 47 [Abstract LB-280]
29. Roché H., Yelle L., Cognetti F., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 25 (2007) 3415-3420
30. Thomas E., Tabernero J., Fornier M., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25 (2007) 3399-3406
31. Perez E.A., Lerzo G., Pivot X., et al. Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone analog, in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25 (2007) 3407-3414
32. Denduluri N., Low J.A., Lee J.J., et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 25 (2007) 3421-3427
33. Low J.A., Wedam S.B., Lee J.J., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23 (2005) 2726-2734
34. Thomas E.S., Gomez H.L., Li R.K., et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25 (2007) 5210-5217
35. Hortobagyi GN, Perez E, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials. In: Proc Am Soc Clin Oncol Breast Cancer Symposium 2008; September 5-8, 2008; Washington, DC, USA [Abstract 186].
36. Pivot X., Villanueva C., Chaigneau L., et al. Ixabepilone, a novel epothilone analog in the treatment of breast cancer. Expert Opin Investig Drugs 17 (2008) 593-599
37. Pivot XB, Lee RK, Thomas ES, et al. Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) resistant to anthracyclines/taxanes: subgroup analysis by estrogen receptor (ER) status. In: Proc Am Soc Clin Oncol Breast Cancer Symposium 2007 [Abstract 221].
38. Pivot XB, Llombart-Cussac A, Martin M, et al. Clinical activity of the novel epothilone B analog, ixabepilone, in triple-negative breast cancer patients. Presented at the 6th European Breast Cancer Conference (EBCC-6); April 15-19, 2008; Berlin, Germany [Abstract 290].
39. Baselga J., Zambetti M., Llombart-Cussac A., et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer: efficacy and safety analyses and identification of biomarkers predictive of response. J Clin Oncol 27 (2009) 526-534
40. Lee H., Xu L., Wu S., et al. Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone. Proc Am Soc Clin Oncol (2006) 24 [Abstract 3011]
41. Rugo H., Thomas E.S., Lee R.K., et al. Combination therapy with ixabepilone plus capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Breast Cancer Res Treat (2007) 106 [Abstract 6069]
42. Perez E., Pivot X., Vrdoljak E., et al. A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. Cancer Res 69 2S (2009) S6140
43. Pivot X., Asmar L., Buzdar A.U., Valero V., and Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82 (2000) 529-534
44. Combination chemotherapy followed by docetaxel or ixabepilone in treating patients who have undergone surgery for nonmetastatic breast cancer. Available at: ; [accessed 13.06.08].